About the Company
We do not have any company description for RECURSION PHARMACEUTICALS, INC. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on RECURSION PHARMACEUTICALS, INC.
Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares
We recently published 10 Stocks Crash as AI Glow Fades. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of Wednesday’s ...
Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid
We recently published 12 Best Healthcare Stocks to Buy Under $30. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the ...
Recursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor ... - Nasdaq
Recursion Pharmaceuticals reported revenues of $10.89 million in the last reported quarter, representing a year-over-year change of -20.4%. EPS of -$0.40 for the same period compares with -$0.31 a ...
Recursion Pharmaceuticals Reports Grant of Inducement Awards as ...
Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today ...
Broker Revenue Forecasts For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher
NasdaqGS:RXRX 1 Year Share Price vs Fair Value Explore Recursion Pharmaceuticals's Fair Values from the Community ...
Azzad Asset Management Inc. ADV Raises Stake in Recursion ...
Recursion Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of ...
Needham Reiterates Recursion Pharmaceuticals Inc - (RXRX) Buy ...
As of August 2, 2023, the average one-year price target for Recursion Pharmaceuticals Inc - is 16.03. The forecasts range from a low of 9.09 to a high of $36.75.
Recursion Pharmaceuticals Inc. (RXRX): Among The Best Medical AI ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) also has major partnerships with key healthcare companies such as Bayer and Genentech for research, which drove up $58 million in sales during 2023.
Recursion Pharmaceuticals’ Earnings Call Highlights Progress and Challenges
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Why Recursion Pharmaceuticals, Inc. (RXRX) Soared Last Week
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) soared 40 percent week-on-week, with the company also experiencing a six-day winning streak as of Friday to close at $10.53 as investor ...
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ETCompany ParticipantsChris Gibson - Co-Founder and ...
Similar Companies
Loading the latest forecasts...